Sansure Biotech Inc. (SHA:688289)
China
· Delayed Price · Currency is CNY 20.44
+0.29 (1.44%)
Jun 16, 2025, 1:44 PM CST
Sansure Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Operating Revenue | 1,508 | 1,424 | 991.1 | 6,304 | 4,342 | 4,598 | Upgrade
|
| Other Revenue | 34.14 | 34.14 | 16.02 | 146.58 | 172.86 | 164.99 | Upgrade
|
| Revenue | 1,543 | 1,458 | 1,007 | 6,450 | 4,515 | 4,763 | Upgrade
|
| Revenue Growth (YoY) | 28.24% | 44.78% | -84.39% | 42.88% | -5.22% | 1203.53% | Upgrade
|
| Cost of Revenue | 316.53 | 279.71 | 280.96 | 2,912 | 1,283 | 971.99 | Upgrade
|
| Gross Profit | 1,226 | 1,178 | 726.15 | 3,538 | 3,232 | 3,791 | Upgrade
|
| Selling, General & Admin | 775.46 | 749.79 | 547.37 | 939.48 | 488.21 | 603.01 | Upgrade
|
| Research & Development | 280.26 | 276.64 | 194.81 | 331.2 | 186.84 | 82.62 | Upgrade
|
| Other Operating Expenses | 16.95 | 10.96 | 0.1 | 27.31 | 12.48 | 11.71 | Upgrade
|
| Operating Expenses | 1,096 | 1,051 | 747.23 | 1,344 | 706.01 | 721.28 | Upgrade
|
| Operating Income | 130.37 | 127.26 | -21.08 | 2,194 | 2,526 | 3,070 | Upgrade
|
| Interest Expense | -19.11 | -18.4 | -2.41 | -2.09 | -0.83 | -0.51 | Upgrade
|
| Interest & Investment Income | 98.03 | 97.53 | 308.41 | 48.35 | 32.53 | 33.06 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.85 | 6.85 | 4.31 | 5.04 | -42.25 | -43.71 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.57 | -1.77 | -9.15 | -7.94 | -1.61 | -0.7 | Upgrade
|
| EBT Excluding Unusual Items | 221.71 | 211.46 | 280.08 | 2,237 | 2,513 | 3,058 | Upgrade
|
| Impairment of Goodwill | - | - | - | -1.44 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -18.74 | -20.44 | 61.84 | 79.24 | 81.01 | 6.23 | Upgrade
|
| Gain (Loss) on Sale of Assets | -3.88 | -4.21 | -7.21 | -5.47 | 0.41 | 0.97 | Upgrade
|
| Asset Writedown | -4.76 | -1.25 | - | -15.1 | - | - | Upgrade
|
| Other Unusual Items | 73.1 | 75.04 | 75.76 | 21.3 | 21.37 | 5.13 | Upgrade
|
| Pretax Income | 267.43 | 260.61 | 410.48 | 2,316 | 2,616 | 3,070 | Upgrade
|
| Income Tax Expense | 33.93 | 34.34 | 62.31 | 379.21 | 373.68 | 453.56 | Upgrade
|
| Earnings From Continuing Operations | 233.5 | 226.27 | 348.17 | 1,937 | 2,243 | 2,617 | Upgrade
|
| Minority Interest in Earnings | 52.81 | 49.32 | 15.55 | 0.09 | 0.17 | - | Upgrade
|
| Net Income | 286.31 | 275.6 | 363.72 | 1,937 | 2,243 | 2,617 | Upgrade
|
| Net Income to Common | 286.31 | 275.6 | 363.72 | 1,937 | 2,243 | 2,617 | Upgrade
|
| Net Income Growth | -25.58% | -24.23% | -81.22% | -13.64% | -14.29% | 6527.90% | Upgrade
|
| Shares Outstanding (Basic) | 585 | 586 | 587 | 585 | 589 | 552 | Upgrade
|
| Shares Outstanding (Diluted) | 585 | 586 | 587 | 585 | 589 | 552 | Upgrade
|
| Shares Change (YoY) | 0.64% | -0.05% | 0.26% | -0.59% | 6.55% | 3.97% | Upgrade
|
| EPS (Basic) | 0.49 | 0.47 | 0.62 | 3.31 | 3.81 | 4.74 | Upgrade
|
| EPS (Diluted) | 0.49 | 0.47 | 0.62 | 3.31 | 3.81 | 4.74 | Upgrade
|
| EPS Growth | -26.06% | -24.19% | -81.27% | -13.12% | -19.56% | 6274.83% | Upgrade
|
| Free Cash Flow | -72.09 | -146.66 | -347.81 | 2,000 | 1,504 | 2,534 | Upgrade
|
| Free Cash Flow Per Share | -0.12 | -0.25 | -0.59 | 3.42 | 2.56 | 4.59 | Upgrade
|
| Dividend Per Share | 0.525 | 0.525 | 0.462 | 1.298 | 0.760 | 0.760 | Upgrade
|
| Dividend Growth | 13.59% | 13.59% | -64.39% | 70.77% | - | - | Upgrade
|
| Gross Margin | 79.48% | 80.82% | 72.10% | 54.85% | 71.58% | 79.59% | Upgrade
|
| Operating Margin | 8.45% | 8.73% | -2.09% | 34.01% | 55.94% | 64.45% | Upgrade
|
| Profit Margin | 18.56% | 18.90% | 36.12% | 30.03% | 49.68% | 54.94% | Upgrade
|
| Free Cash Flow Margin | -4.67% | -10.06% | -34.53% | 31.01% | 33.32% | 53.19% | Upgrade
|
| EBITDA | 280.94 | 267.89 | 79.8 | 2,269 | 2,571 | 3,096 | Upgrade
|
| EBITDA Margin | 18.21% | 18.37% | 7.92% | 35.18% | 56.96% | 65.01% | Upgrade
|
| D&A For EBITDA | 150.57 | 140.63 | 100.88 | 75.47 | 45.89 | 26.68 | Upgrade
|
| EBIT | 130.37 | 127.26 | -21.08 | 2,194 | 2,526 | 3,070 | Upgrade
|
| EBIT Margin | 8.45% | 8.73% | -2.09% | 34.01% | 55.94% | 64.45% | Upgrade
|
| Effective Tax Rate | 12.69% | 13.18% | 15.18% | 16.37% | 14.28% | 14.77% | Upgrade
|
| Revenue as Reported | 1,543 | 1,458 | 1,007 | 6,450 | 4,515 | 4,763 | Upgrade
|
| Advertising Expenses | - | 68.07 | 26.28 | 36.36 | 32.38 | 27.94 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.